ArticleVaccines2024

Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18-49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study.

Yanxia Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.